CEACAM1 mediates B cell aggregation in central nervous system autoimmunity

Area of Science:

• Neuroimmunology
• Cellular and Molecular Immunology

Background:

• B cell aggregates in the central nervous system (CNS) correlate with rapid multiple sclerosis (MS) progression.
• Understanding the mechanisms of B cell aggregate formation is crucial for developing effective MS therapies.

Purpose of the Study:

• To investigate the role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in B cell aggregate formation in MS.
• To evaluate CEACAM1 as a potential therapeutic target for MS.

Main Methods:

• Analysis of CEACAM1 expression on B cells from MS patients and in a mouse model of MS.
• In vitro assessment of anti-CEACAM1 antibodies on B cell aggregation.
• In vivo administration of anti-CEACAM1 antibodies in a mouse model of MS.

Main Results:

• CEACAM1 expression was elevated on peripheral blood B cells and detected in CNS infiltrates of MS patients.
• Anti-CEACAM1 antibodies blocked B cell aggregation in vitro and reduced CNS B cell aggregates in vivo.
• Treatment with anti-CEACAM1 antibody attenuated established MS-like disease in mice without adverse effects.
• CEACAM1 co-expression with T cell immunoglobulin and mucin domain -3 (TIM-3) on B cells correlated with autoreactive T helper cells.

Conclusions:

• CEACAM1 plays a critical role in B cell aggregate formation in MS.
• CEACAM1 represents a promising therapeutic target for MS treatment.
• Targeting CEACAM1 may offer new avenues for managing MS pathogenesis.